TREM2 Deficiency Reprograms Gut Macrophages and Microbiota to Enhance Anti-PD-1 Tumor Immunotherapy Background Immune checkpoint inhibitors (CPIs), such as drugs that block programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), have been successfully used to activate anti...

The Tumor Lactate-SREBP2 Signaling Pathway Drives Tolerogenic Dendritic Cell Maturation and Promotes Cancer Progression In recent years, the critical role of dendritic cells (DCs) in antitumor immunity has been widely recognized. However, many cancers cause DC dysfunction through mechanisms that are not fully understood. In a newly published study ...

Research Progress in Cancer Immunology: Tumor-derived Antigen Signals Induce CD8+ T-cell Exhaustion Localized to the Tumor Site Research Background and Purpose In recent years, immunotherapy has shown great potential in cancer treatment. However, tracking the behavior of immune cells after receiving antigen signals remains a challenge. Within tumor...

A Panoramic View of Whole Genome Repetitive Sequences in Cancer and Circulating Free DNA Research Background and Significance Throughout the development of cancer and other diseases, genetic changes in repetitive sequences within the genome are a significant characteristic. However, standard sequencing methods struggle to effectively characterize t...

Tumor-Associated NK Cells Drive MDSC-Mediated Tumor Immune Tolerance via the IL-6/STAT3 Axis — Research by Neo et al. In recent years, researchers have delved deeply into the mechanisms of tumor immune escape to improve the success rate of cancer immunotherapy. The accumulation of CD8 T cells in the tumor microenvironment is a critical determinant ...

Using the Suppression of Cytoplasmic Iron-Sulfur Cluster Assembly to Restore PTEN and Inhibit Glioma Stem Cells Background Glioblastoma (GBM) is one of the most lethal primary brain tumors. Glioma stem cells (GSCs) not only initiate and sustain the malignant phenotype but also enhance treatment resistance. Although PTEN frequently mutates in gliobl...

Scientists Reveal the Anti-Tumor Mechanism of Src Inhibitors in IDH Mutant Cholangiocarcinoma Background Introduction In recent years, the incidence of intrahepatic cholangiocarcinoma (ICC) has been rising worldwide. ICC is a highly invasive tumor usually lacking noticeable symptoms in the early stages, with cases often being inoperable by the time...

Interactive Mechanisms Between Cancer Cells and Macrophages Facilitate Pancreatic Cancer Cachexia Background Pancreatic cancer is currently the third leading cause of cancer-related death in the United States and is expected to become the second leading cause of cancer death within the next decade. Unfortunately, more than 80% of pancreatic cancer ...

Intrinsic Epigenetic Dysregulation in Tumor Cells Shapes Cancer-Associated Fibroblasts Heterogeneity to Metabolically Support Pancreatic Cancer Authors Ningning Niu, Qingshen Xu, Wang Zheng, …, Kurong Jiang, Fengshi Yu, Xue Xu Jing published an article titled “Intrinsic Epigenetic Dysregulation in Tumor Cells Shapes Cancer-Associated Fibroblasts He...

Applying STING Function to BH3-Mimetic Drugs for Treating TP53 Mutant Blood Cancers In the recently published article in Cancer Cell titled “Putting the sting back into BH3-mimetic drugs for TP53-mutant blood cancers,” Sarah T. Diepstraten and colleagues conducted in-depth research to explore how to enhance the efficacy of BH3-mimetic drugs in TP53...